Ampio Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and Warrants

ENGLEWOOD, CO., August 9, 2018 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) (“Ampio”), a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock and warrants to purchase up to 20,000,000 shares of common stock, at a combined purchase price of $0.40 per share of common stock and accompanying warrant, with anticipated gross proceeds of $8.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Ampio. The warrants are exercisable six months after issuance at a price of $0.40 per share of common stock and have a term of five years commencing six months after issuance. The offering is expected to close on or about August 13, 2018, subject to customary closing conditions.

All of the securities in the offering are to be sold by Ampio. Ampio intends to use the net proceeds from this offering for working capital and general corporate purposes, including continued preclinical development of Ampion and funding an Ampion clinical trial, if required.

Canaccord Genuity is acting as sole book-running manager for the offering.

The sale of the common stock and the accompanying warrants to purchase shares of common stock is being offered by Ampio pursuant to a shelf registration statement on Form S-3 (Registration No. 333-217094), which was declared effective by the Securities and Exchange Commission (the “SEC”) on April 20, 2017. A final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC, will be available on the SEC’s website at and will form a part of the effective registration statement. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained, when available, by contacting Canaccord Genuity LLC, 99 High Street, Suite 1200, Boston, MA 02110, Attn: Syndicate Department, by telephone at (617) 371-3900 or by e-mail at

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or jurisdiction.

About Ampio Pharmaceuticals:
Ampio Pharmaceuticals, Inc. is a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options.  We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Investor Contact:
Tom Chilcott
Chief Financial Officer
Phone: (720) 437-6500

Forward Looking Statements:
This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the public offering of Ampio’s common stock and warrants. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ, including the satisfaction of customary closing conditions related to the public offering, as well as other factors, are discussed in the risks and uncertainties detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.